<DOC>
	<DOCNO>NCT02192853</DOCNO>
	<brief_summary>The investigator want estimate endothelial plasma activity dipeptidyl peptidase 4 different dos sitagliptin healthy subject patient type 2 diabetes . Furthermore , investigator want investigate whether current clinical dose 100 mg sitagliptin sufficient inhibit plasma endothelial activity enzyme dipeptidyl peptidase 4 .</brief_summary>
	<brief_title>Correlation Between Plasma- Endothelial DPP-4 Activity</brief_title>
	<detailed_description>The two incretin hormone glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotropic polypeptide ( GIP ) secrete intestinal L- K- cell , respectively response ingestion nutrient . The two hormone able low blood glucose level high glucose level - call incretin effect . GIP GLP-1 rapidly inactivate enzyme dipeptidyl peptidase 4 ( DPP-4 ) . The remain metabolite without insulinotropic effect . The effect DPP-4 inhibitor use treatment type 2 diabetes relies impact DPP-4 activity . DPP-4 exists soluble form plasma ad membrane-bound form blood vessel tissue . The impact DPP-4 inhibitor DPP-4 activity evaluate plasma . We aim investigate plasma endothelial DPP-4 activity ( i.e . whole-body DPP-4 activity ) patient type 2 diabetes different dos DPP-4 inhibitor sitagliptin . Both healthy control subject patient type 2 diabetes subject 4 experimental day ( randomized order ) continuous infusion GLP-1 pre-treatment 25 mg sitagliptin , 100 mg sitagliptin , 200 mg sitagliptin placebo , respectively . Afterwards , go measure whole-body DPP-4 activity compare plasma level active ( intact ) GLP-1 total GLP-1 , relate plasma DPP-4 activity .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Caucasians diet and/or metformin treat patient type 2 diabetes ( diagnose accord criterias World Health Organization ) Normal Hemoglobin Prior Informed Consent Nephropathy Liver disease Inflammatory bowel disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Glucagon-like peptide 1</keyword>
	<keyword>Dipeptidyl peptidase 4</keyword>
	<keyword>Dipeptidyl peptidase 4 inhibitor</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>Enzyme activity</keyword>
</DOC>